Hyperlipoproteinemia Type III: Clinical Trials

1 trial for Hyperlipoproteinemia Type III, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1 unknown. 1 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 41Unknown 1

Follow Hyperlipoproteinemia Type III: new trials by email Literature Review of Hyperlipoproteinemia Type III trials Research Report on Hyperlipoproteinemia Type III

Trials (filtered) newest first · largest first

All 1 trial

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Effects of Evolocumab Versus Placebo Added to Standard Lipid-lowering Therapy on Fasting and Post Fat Load Lipids in Patients With Familial Dysbetalipoproteinemia
Evolocumab Auto-Injector [Repatha], Placebos - Familial Dysbetalipoproteinemia, Hyperlipoproteinemia Type III
Phase 4UnknownUMC Utrecht302019-08-012019-01-22

Broader conditions

Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1)  ·  Dyslipidemias (1)  ·  Genetic Diseases, Inborn (1)  ·  Hyperlipidemias (1)  ·  Hyperlipoproteinemias (1)  ·  Lipid Metabolism Disorders (1)  ·  Lipid Metabolism, Inborn Errors (1)  ·  Metabolic Diseases (1)  ·  Metabolism, Inborn Errors (1)  ·  Nutritional and Metabolic Diseases (1)

Interventions

evolocumab (1)

Sponsors

UMC Utrecht (1)

Top investigators

Frank LJ Visseren, prof (1)